( COLLEGEVILLE Pa. March 30 2007 /PRN...)Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo,Health

COLLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , Solvay Pharmaceuticals, Inc. and Lundbeck A/S presented clinical study results on bifeprunox at an international medical congress this week. Safety analyses suggest bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, was associated with a favorable weight and lipid profile, similar to placebo. In addition, increases in weight occurred in patients receiving active references versus placebo.

The analyses presented this week are based on further evaluation of clinical studies presented last year, which illustrated that, in a six-month trial, bifeprunox maintained stability in patients with stable schizophrenia versus placebo. In six-week trials, bifeprunox improved symptoms in patients with acute exacerbations of schizophrenia but showed a smaller mean effect than did active references versus placebo.

"Data from Phase 2 and Phase 3 trials suggest that, if approved, bifeprunox may be an important treatment option for stable patients with schizophrenia -- particularly because of our concerns about the high prevalence of metabolic syndrome in this patient population," says Herbert Y. Meltzer, M.D., Professor of Psychiatry and Director of the Division of Psychopharmacology, Vanderbilt University Medical Center. "If approved, bifeprunox may be an important alternative for treating adult patients with schizophrenia over the long term."

A synopsis of new abstracts containing bifeprunox data presented at the meeting follows.

    Metabolic and Safety Parameters of Bifeprunox


    -- In analyses of data from Phase 3, six-week, randomized, double-blind,

       placebo-controlled active-referenced studies:

       * Bifeprunox had favorable effects on total cholesterol, triglycerides

         (TG), very low-density lipoprotein and low-density lipoprote
'"/>




Page: 1 2 3 4 5 6 
Related medicine technology :

1. Managing Preanalytical Processes for Patient Safety
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and
Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination
Therapy in Treatment-Experienced Adults With HIV
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Quadramet at International Myeloma Workshop
5. New Proof of Genisteins Efficacy and Safety for Osteopenia and
Osteoporosis Published in Annals of Internal Medicine
6. First Phase II Short-Term Study on Dapagliflozin Shows Results on
Safety, Tolerability and Glycemic Markers in Subjects With Type 2
Diabetes
7. Phase IIIb Clinical Data Validate the Overall and Cardiovascular
Safety Profile of Cycloset (A Quick Release Formulation of
Bromocriptine Mesylate) in Patients with Type 2 Diabetes
8. Neurologix Announces Publication of Landmark Gene Therapy Study
Demonstrating Safety and Statistically Significant Improvement in
Patients With Advanced Parkinsons Disease
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace
Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. Enbrel Safety Data for up to Eight Years in Patients with Juvenile
Rheumatoid Arthritis Being Presented at EULAR
11. Repros Reports That Proellex Has Demonstrated Superior Efficacy and
Safety in Endometriosis When Compared to Standard of Drug Care